A Randomized, Double-Blind, Two Treatment, Two Period, Chronic Dosing (2 Weeks), Cross-Over, Multi-Center Study to Evaluate the Effects of PT001 and PT005 on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD.
Phase of Trial: Phase III
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Formoterol (Primary) ; Glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Pearl Therapeutics
- 29 Mar 2018 Status changed from active, no longer recruiting to recruiting.
- 22 Mar 2018 Planned End Date changed from 5 Mar 2018 to 5 Feb 2019.
- 22 Mar 2018 Planned primary completion date changed from 5 Mar 2018 to 31 May 2018.